H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BiomX today and set a price target of $15.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising developments in BiomX’s clinical trials. The initiation of the Phase 2b study of BX004 for treating chronic respiratory infections in cystic fibrosis patients is a significant step forward, building on the positive outcomes from the earlier Phase 1b/2a study. The previous study showed that 14.3% of patients experienced complete infection clearance, which is particularly impressive given the chronic nature of these infections.
Furthermore, the design of the Phase 2b study, which is randomized, double-blind, and placebo-controlled, aims to evaluate multiple efficacy endpoints such as bacterial burden reduction and lung function improvement. The planned discussions with the FDA in the second half of 2025 regarding real-world evidence and regulatory alignment could potentially streamline the approval process. Additionally, the positive Phase 2 results for BX211 in diabetic foot osteomyelitis further support the potential of BiomX’s pipeline, contributing to the Buy rating.